Cancer Clinical Research Trials

The Thomas Johns Cancer Hospital is committed to offering our patients opportunities to participate in new clinical research trials.  This is part of our mission in offering the most advanced services available.  These trials are open to those who qualify.  Our research nurse coordinators will work with your physicians to discuss trials with you and your family. To learn if you qualify for these or other clinical research trials, please speak with your physician.  Studies opened and managed by the Virginia Cancer Institute (VCI) are noted as well as any study pending Institutional Review Board (IRB) approval.   

Protocols Open at TJCH:

Breast Cancer

BRE 163 - SCRI
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women with Node Positive or High Risk Node Negative, HE2 Negative Breast Cancer. VCI Study

BRE 154 - SCRI
A Randomized, Double-Blind, Placebo-controlled Phase II Trail of Weekly Taxol /Bevacizamab+/- Everolimus as First-Line Chemotherapy for Patients with HER-2 Negative Metastatic Breast Cancer. VCI Study

BRE 133 - SCRI
Phase II Study of Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER2-Negative Breast Cancer. VCI Study

BRE 128 - GSK EGF106708 ALTTO
A Randomized, Multi-Center, Open-
Label, Phase III Study of Adjuvant
Lapatinib, Trastuzumab, Their Sequence
and Their Combination in Patients with
HER2/ErbB2 Positive Breast Cancer.
VCI Study

BRE 139 – SCRI
Phase II Study of Neoadjuvant
Ixabepilone/Carboplatin/Trastuzumab in
HER2-Positive Locally Advanced Breast
Cancer.  VCI Study

BRE 140 - GSK LPT 111111
A Single-arm, Multicenter Phase II
Study to Evaluate The Combination of
Weekly Nanoparticle Albumin-bound
Paclitaxel (Nab-Paclitaxel or Abraxane)
and Lapatinib (TYKERB) in Women
who have received no more than one
prior chemotherapeutic regimen in the
treatment of ErB2 Over expressing
Metastatic Breast Cancer.  VCI Study

BRE 145 – SCRI
Phase III Study of Doxorubicin /
Cyclophosphamide (AC) Followed by
Ixabepilone vs. AC Followed by
Paclitaxel in Patients with Triple-
Negative Early-Stage Breast Cancer. 
VCI Study

SCRI BRE 156
A Phase II Study of NK012 in Locally
Advanced Non-Resectable and
Metastatic Breast Cancer Patients with
Triple Negative Phenotype.  VCI Study

BRE 153 - Lilly B9E-US-S379
A Phase 2 Study of Gemcitabine and
Bevacizumab as First-Line Treatment in
HER2 Negative, Locally Recurrent or
Metastatic Breast Cancer Previously
Treated with Taxanes.  VCI Study

ECOG PACCT-1/CTSU
Program for the Assessment of Clinical
Cancer Tests (PACCT-1):
IndividuaLized Options for Treatment
The TAILORx Trial.  VCI Study

BRE 144 - SNDX 275-0301
A Phase 2, Randomized, Double-
Blind, Multicenter Study of
Exemestane with and without
SNDX-275 in Postmenopausal
Women with Locally Recurrent
or Metastatic Estrogen Receptor
Positive Breast Cancer,
Progressing on Treatment with a
Non-Steroidal Aromatase
Inhibitor.  VCI Study

SWOG S05000
A Randomized Phase III Trial to
test the strategy of Changing
Therapy versus Maintaining
Therapy for Metastatic Breast
Patients who have Elevated
Circulating Tumor Cell Levels at
First Follow-up Assessment. 
VCI Study

VCU-Walters/MCC-0459
PNI-Based Stress Management in Early
Breast Cancer. VCI Study

VCU-Bradley
Breast Cancer, Health Insurance and Work study. VCI Study

HEPATOCELLULAR

GI 106 PANCREATIC
A Phase II Study of Lenalidomide
in Combination with Gemcitabine
in Patients with Untreated
Advanced Carcinoma of the
Pancreas. VCI study

GI 121 - Pfizer, Inc. A6181170
A Multinational, Randomized,
Open-Label, Phase 3 Study of
Sunitinib Malate versus Sorafenib
in Patients with Advanced
Hepatocellular Carcinoma.  VCI Study

LUNG

SCRI LUN 186
Phase II Trial of Preoperative
Pemetrexed and Carboplatin in
Patients with Select Stage IB, II
and III Non-Squamous NSCLC. VCI study

SCRI LUN 196
Randomized Phase II Trial of
Pemetrexed vs. Pemetrexed /
Bevacizumab vs. Pemetrexed /
Carboplatin / Bevacizumab in
Patients with Stage IIIB / IV Non-
Small-Cell Lung Cancer and
ECOG Performance Status. VCI study

LUN 195 – Genentec OAM4558g
A Randomized, Phase II, Multi-Center, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Activity of MetMab with Tarceva in Patients with Advanced NSCLC. VCI Study

LUN 198 - Nippon A6012212US
A Phase II Study of NK012 in Sensitive and Refractory Relapsed Small-Cell Lung Cancer (SCLC). VCI Study

LUN 189 – Pfizer A7471017
A Phase II Open Label Trial of
PF-00299804 in Untreated
Advanced Adenocarcinoma of the
Lung in Never or Former Light
Smokers. VCI Study

LUN 192 – Lilly H3E-MCJMHD
Randomized, Open-Label, Phase
3 Study of Pemetrexed plus
Carboplatin and Bevacizumab
Followed by Maintenance
Pemetrexed and Bevacizumab
versus Paclitaxel plus Carboplatin
and Bevacizumab Followed by
Maintenance Bevacizumab in
Patients with Stage IIIb or IV
Nonsquamous Non-Small Cell
Lung Cancer. VCI Study 
 

LYMPHOMA

LYM 64 - Cephalon C18083
An Open Label, Randomized, Study of Bendamustine and Rituxan (BR) versus Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in the First Line Treatment of Patients with Advanced Indolent Non-Hodgkin’s Lymphoma  or Mantle Cell Lymphoma. VCI Study

LYM 54 - Lilly H6Q-MC-S028
An Open Label, Randomized,
Phase 2 Study of R-CHOP Plus
Enzastaurin versus R-CHOP in
the First-Line Treatment of
Patients with Intermediate and
High-Risk Diffuse B –Cell NHL.
VCI Study

MYELOMA

MM22 - Millennium-C05009
Randomized Phase 3b Study of
Three Treatment Regimens in
Subjects with Previously
Untreated Multiple Myeloma
Who Are Not Considered
Candidates for High-Dose
Chemotherapy and Autologous
Stem Cell Transplantation:
Velcade ,Thalodomide, and
Dexamethasone (VTD) versus
Velcade and Dexamethasone
(VD) versus Velcade, Melphalan
And Prednisone (VMP). VCI Study

PROSTATE

SCRI-GU 48 - AZ D430C00033
A Phase lll Randomized, Doubleblind,
Placebo-controlled Study to
Assess the Efficacy and Safety of
10 mg ZD4054 in Combination
with Docetaxel in Comparison
with Docetaxael in Patients with
Metastatic Hormone-resistant Prostate Cancer.
VCI Study

RTOG 0534 
A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy; CJW2009-012

RENAL CELL

GU 58 – Pfizer A4061032
Axitinib (AG-013736) as Second Line Therapy for Metastatic Renal Cell Cancer. VCI Study

GU 59 – GSK VEG108844
A Study of Pazopanib versus Sunitinib in the Treatment of Locally Advanced or Metastatic Renal Cell Carcinoma. VCI Study

GU 56 – SCRI
A Phase II Trial of Pazopanib in
Patients with Metastatic Renal
Cell Carcinoma Previously
Treated with Sunitinib or
Bevacizumab.  VCI Study

UNKNOWN PRIMARY

UNK PRI 21/TopoTarget A/S
PXD101-CLN-17
An open-label randomized phase
II trial of belinostat (PXD101) in
combination with carboplatin and
paclitaxel (BelCaP) compared to
carboplatin and paclitaxel in
patients with previously untreated
carcinoma of unknown primary. VCI Study

OTHER

CNS 10
A Phase II Study of Concurrent RT, Temodar, and Avastin followed by Avastin /Everolimus in the 1st Line Treatment of Patients with Glioblastoma. VCI Study

Partial Breast Irradiation
A prospective evaluation of catheter failure rates and skin reactions in patients receiving accelerated partial breast irradiation; CJW2007-008

National Oncology PET Registry (NOPR)
This study is a registry with the aim of determining clinical benefit in designing individual care plans based on information obtained from additional tests; CJW2009-004.

Cancer Survivorship 
A trial for cancer survivors to determine education and supportive service needs; CJW2007-017